Emmaus Life Sciences Reports Quarterly Financial Results

Core Insights - Emmaus Life Sciences, Inc. reported a 48% decline in net revenue for Q2 2025 compared to the same period in 2024, primarily due to competition from generic L-Glutamine, despite a 33% reduction in operating expenses [2][3]. Financial and Operating Results - Net Revenues: For the three months ended June 30, 2025, net revenues were $2.8 million, down from $5.4 million in Q2 2024, attributed to decreased U.S. sales due to generic competition [3]. - Operating Expenses: Total operating expenses decreased to $3.0 million from $4.6 million in the same period in 2024, mainly due to reductions in selling and administrative expenses following a workforce reduction in Q4 2024 [4]. - Income (Loss) From Operations: The company reported a loss from operations of $0.4 million compared to an income of $0.6 million in Q2 2024, driven by the decline in net revenues [5]. - Other Expense: Other expenses were $1.4 million, down from $2.7 million in Q2 2024, mainly due to a decrease in the fair value of derivative liabilities and a nonrecurring gain from lease modification, partially offset by increased interest expenses [6]. - Net Loss: The net loss for the quarter was $1.1 million, or $0.02 per share, compared to a net loss of $2.2 million, or $0.03 per share, in Q2 2024, reflecting a decrease in other expenses [7]. Liquidity and Capital Resources - As of June 30, 2025, the company had cash and cash equivalents of $0.9 million, down from $1.4 million at the end of 2024 [8]. Company Overview - Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on treating sickle cell disease, with its product Endari® approved for marketing in several countries [9][10].